We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

By LabMedica International staff writers
Posted on 25 May 2023
Print article
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding. This process transforms liquid blood into a gel-like state, leading to blood coagulation. In the absence of hemostasis, even minor injuries could result in excessive blood loss and potentially prove fatal. Therefore, it is important to assess the body's ability to maintain hemostasis. Presently, a multitude of tests and procedures exist to evaluate the body's capacity to control bleeding, including Complete blood count (CBC), Prothrombin time (PT) and international normalized ratio (INR), Activated partial thromboplastin time (aPTT), Platelet function tests, and D-dimer test, among others.

The global hemostasis diagnostics market is projected to grow from USD 2.28 billion in 2018 to USD 3.95 billion by 2025, driven by factors such as an increase in blood clotting disorders, growing awareness about these conditions, and rising healthcare spending. Moreover, concerted efforts by government entities and healthcare organizations to improve the diagnosis and treatment of rare diseases, technological advancements in healthcare, increased surgical procedures, and higher R&D investments are set to aid market growth. These are the latest findings of Brandessence Market Research (London, UK), a market research firm.

Surgical procedures, which involve the prevention of excessive bleeding, are anticipated to be a significant growth driver for the global hemostasis diagnostics market. Before surgery, hemostasis diagnostic tests are essential to verify a positive hemostatic status in the patient, ensuring optimal outcomes and reducing complications such as excessive bleeding or clotting. Additionally, the hemostasis diagnostics market has seen an influx of advanced technologies, improving the accuracy, speed, and convenience of testing. Techniques like point-of-care testing (POCT), automation, and molecular diagnostics have increased the efficiency and reliability of hemostasis tests, contributing to market growth. Nonetheless, accurately diagnosing hemostatic disorders is a complex task, which is hampering market growth.

In terms of product type, point-of-care testing systems are projected to command the largest share of the hemostasis diagnostics market from 2022-2029 due to their convenience, affordability, and accessibility. Among test types, the D Dimer segment is expected to hold the majority share over the same period due to the high efficacy, affordability, and non-invasive nature of such tests. The rise of personalized medicine is expected to focus on genetic testing and molecular diagnostics in the field of hemostasis diagnostics.

Geographically, the Middle East & Africa (MEA) region is projected to hold the largest share of the global hemostasis diagnostics market from 2022-2029, driven by increased awareness of hemostatic disorders, a growing elderly population, and a rise in surgical procedures. Moreover, a rapidly evolving healthcare infrastructure, increased healthcare spending, and technological advancements will further bolster the MEA market for hemostasis diagnostics. The European hemostasis diagnostics market is expected to experience the fastest growth due to increased healthcare spending, a rising incidence of blood clotting disorders, and a surge in R&D investments. The growth of personalized medicine, heightened awareness of rare disorders, and the presence of key players will further fuel the growth of the European hemostasis diagnostics market.

Related Links:
Brandessence Market Research 

Unit-Dose Twist-Tip BFS
Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
Platinum Supplier
Diagnostic Reader
Acucy System
New
Automated Chemistry Analyzer
TC-Matrix 600

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Molecular Diagnostics

view channel
Image: New algorithm can predict diabetic kidney disease (Photo courtesy of Freepix)

AI Algorithm Predicts Diabetic Kidney Disease through Blood Tests

Diabetes is globally recognized as the main contributor to kidney failure. Notable advancements have been made in devising treatments for kidney disease in diabetic patients. Yet, evaluating an individual's... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: navify digital solutions can helping labs mitigate unique quality challenges (Photo courtesy of Roche)

Cloud-Based Digital Solution Allows Labs to Track Test Samples along Entire Diagnostic Journey

Diagnosing a disease involves a meticulous procedure of monitoring a patient's diagnostic sample throughout its entire journey, which aids in clinical decision-making. However, there aren't any standardized... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.